Relapsed immune thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus: a case report and literature review
10.3760/cma.j.cn121090-20241128-00489
- VernacularTitle:继发于系统性红斑狼疮的复发免疫性血栓性血小板减少性紫癜1例报告并文献复习
- Author:
Hong TIAN
1
;
Yun LI
1
;
Haiju HE
1
;
Xiaoyan XU
1
;
Ziqiang YU
1
;
Jie YIN
1
Author Information
1. 国家血液系统疾病临床医学研究中心，江苏省血液研究所，苏州大学附属第一医院，国家卫生健康委员会血栓与止血重点实验室，苏州 215006
- Publication Type:Journal Article
- Keywords:
Immune thrombotic thrombocytopenic purpura;
Relapse;
Systemic lupus erythematosus;
Bortezomib
- From:
Chinese Journal of Hematology
2024;45(S1):12-17
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To review the diagnosis and treatment process of a patient with relapsed immune thrombotic thrombocytopenic purpura (iTTP) secondary to systemic lupus erythematosus (SLE) and conduct a review of relevant literature, so as to provide a reference basis for the diagnosis and treatment of this disease.Methods:We retrospectively analyzed the diagnosis and treatment process of a patient with relapsed iTTP secondary to SLE who was admitted to the First Affiliated Hospital of Soochow University, and conducted a review of literature.Results:When the patient's iTTP relapsed, it was accompanied by moderate lupus activity, hypofibrinogenemia, renal insufficiency, and pulmonary infection. After adopting therapeutic plasma exchange (TPE), hormone pulse therapy, bortezomib, and comprehensive diagnosis and treatment by a multidisciplinary team, both the patient's iTTP and SLE were relieved.Conclusion:A comprehensive examination should be completed when diagnosing iTTP to rule out the possibility of combining with other autoimmune diseases. For relapsed and refractory cases, treatments targeting plasma cells, such as bortezomib, can be attempted.
